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Serum c-reactive protein (CRP) was suggested for the assessment of intermediate cardiovascular (CV) risk. Here, systemic or
intraplaque CRP levels were investigated as predictors of major adverse cardiovascular events (MACEs) in patients with severe
carotid stenosis. CRP levels were assessed in the serum andwithin different portions (upstream and downstream) of carotid plaques
of 217 patients undergoing endarterectomy. The association between CRP and intraplaque lipids, collagen, neutrophils, smooth
muscle cells (SMC), and macrophage subsets was determined. No correlation between serum CRP and intraplaque biomarkers
was observed. In upstream portions, CRP content was directly correlated with intraplaque neutrophils, total macrophages, and M1
macrophages and inversely correlated with SMC content. In downstream portions, intraplaque CRP correlated with M1 and M2
macrophages. According to the cut-off point (CRP > 2.9%) identified by ROC analysis in upstream portions, Kaplan-Meier analysis
showed that patients with high CRP levels had a greater rate of MACEs. This risk of MACEs increased independently of age, male
gender, serum CRP, and statin use. In conclusion, in patients with severe carotid artery stenosis, high CRP levels within upstream
portions of carotid plaques directly and positively correlate with intraplaque inflammatory cells and predictMACEs at an 18-month
follow-up period.
1. Introduction
It is widely established that both adaptive and innate immu-
nity tightly regulate atherogenesis [1]. Several soluble and
intraplaque inflammatory mediators have been shown to
variably influence immune and vascular cell functions. One
of the most studied inflammatory molecules is c-reactive
protein (CRP), a short pentraxin produced by the liver in
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response to interleukin- (IL-) 6 following a microbial trigger
or tissue damage [2]. In human beings, CRP is considered
as an acute phase protein, with serum levels ranging from
less than 1.0mg/L at baseline to up to 1000-fold higher levels
during acute response [2]. CRP can bind to oxidized or
degraded low-density lipoprotein (LDL) activating comple-
ment; it can induce the expression of adhesion molecules,
mediate the uptake of LDL-cholesterol by macrophages,
stimulate monocyte recruitment within the arterial wall, and
increase the production of chemokines, such as monocyte
chemoattractant protein-1 [3–5]. Over the past two decades,
CRP has been tested for clinical use as a sensitive, non-
specific systemic marker of infection, inflammation, and
tissue damage. In particular, it has been highlighted as a
promising marker of coronary heart disease, ischemic stroke
and cognitive impairment, vascularmortality, and death from
different cancers [6, 7]. However, the impact of CRP as a
predictor of cardiovascular (CV) events has been weakened
by Danesh and colleagues [8]. Given the strong association
that exists between chronic inflammatory diseases and the
increased risk of coronary artery diseases, the question has
been raised as to whether CRP is an innocent bystander of or
an active player in proatherosclerotic mechanisms [9].
Carotid artery stenosis represents an independent risk
factor for ischemic cerebrovascular disease and a direct cause
of cognitive impairment, with an estimated prevalence of
9.3% for patients older than 70 years [10, 11]. In the Caucasian
population, carotid atherosclerosis is usually found at the
carotid artery bifurcation, involving the distal common
carotid and the proximal internal carotid arteries. Systemic
and intraplaque inflammation have been suggested to be
potentially associated with plaque vulnerability [12]. Serum
high sensitivity- (hs-) CRP has already been demonstrated
as being directly correlated with carotid plaque vulnerability
[13–15]. However, intraplaque CRP has been poorly inves-
tigated in human carotid plaques [15]. In coronary arteries,
smooth muscle cells (SMC) have been found to release CRP
in response to inflammatory cytokines [16, 17], underscoring
a potential proatherosclerotic role of CRP in plaque rupture
and thrombosis [18].
In the present study, we investigated the potential cor-
relations between serum and intraplaque CRP levels and
intraplaque inflammatory and vascular cells in patients with
severe carotid artery stenosis. Furthermore, considering
plaque heterogeneity, we assessed the potential prognostic
value that CRP values of upstream and downstream portions
of carotid plaques could have on major adverse cardiovascu-
lar events (MACEs) at 18-month follow-up.
2. Methods
2.1. Patients and Clinical Assessment. From March 2008 to
June 2011, we enrolled 269 patients with extra cranial, high-
grade stenosis (>70% luminal narrowing) of the internal
carotid artery in an observational cohort at a single center
(IRCCS Azienda Ospedaliera Universitaria San Martino-
IST Istituto Nazionale per la Ricerca sul Cancro, Genoa,
Italy). Some of the samples have already been used for
analysis and published [19–21]. Among the total cohort (𝑛 =
Table 1: Clinical characteristics of the overall cohort at admission.
Overall cohort (𝑛 = 217)
Demographics
Age, yr. (IQR) 72 (67.0–77.5)
Males, number (%) 136 (62.7)
Systolic BP∗, mmHg (IQR) 135 (130–143.75)
Diastolic BP, mmHg (IQR) 80 (80–90)
Waist circumference, cm (IQR) 90 (87–97)
Carotid stenosis, % (IQR) 80 (70.0–85.0)
Hypertension, number (%) 157 (72.4)
Active smokers, number (%) 54 (24.9)
Previous smokers, number (%) 93 (42.9)
Type 2 diabetes, number (%) 42 (19.4)
Dyslipidaemia, number (%) 125 (57.6)
Chronic CAD†, number (%) 41 (18.9)
Medications
RAAS‡ inhibitors, number (%) 109 (50.2)
ACE-I§, number (%) 13 (6.0)
ARBs‖, number (%) 96 (44.2)
𝛽-Blockers, number (%) 59 (27.2)
Calcium antagonists, number (%) 67 (30.9)
Diuretics, number (%) 28 (12.9)
Statins, number (%) 114 (52.5)
Antiplatelet drugs, number (%) 221 (82.2)
Aspirin, number (%) 129 (59.4)
Thienopyridine, number (%) 51 (23.5)
Anticoagulants (heparin), number (%) 11 (5.1)
Oral antidiabetics, number (%) 28 (12.9)
Insulin, number (%) 8 (3.7)
Data are expressed as median (interquartile range [IQR]) or number
(percentages [%]).
∗BP: blood pressure.
†CAD: coronary artery disease.
‡RAAS: renin-angiotensin-aldosterone system.
§ACE-I: angiotensin converting enzyme inhibitor.
‖ARBs: angiotensin receptor blockers.
269), 52 carotid endarterectomies were missing, leaving 217
samples available for analysis in the present substudy. As
previously described [22], all patients had undergone carotid
endarterectomy (CEA) according to the recommendations
published by the North American Symptomatic Carotid
Endarterectomy Trial [23], the European Carotid Surgery
Trial [24], and the Asymptomatic Carotid Surgery trial [25].
The Ethics Committee of IRCCS Azienda Ospedaliera Uni-
versitaria San Martino-IST Istituto Nazionale per la Ricerca
sul Cancro inGenoa, Italy, approved this protocol, performed
in accordance with the guidelines of the Declaration of
Helsinki. Patients gave informed consent before entering
the study. On the day prior to CEA, serum samples were
obtained to evaluate circulating markers of cardiovascular
vulnerability. Medications are reported in Table 1 and were
not modified in the 2 months prior to enrolment. Exclusion
criteria were as follows: spontaneous cerebral embolism up
to 30minutes preoperatively or during the dissection phase of
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the operation, malignant hypertension, acute coronary artery
diseases, any cardiac arrhythmias, congestive heart failure
(II, III, and IV New York Heart Association classes), liver or
renal disorder or function abnormalities, acute and chronic
infectious diseases, autoimmune and rheumatic diseases,
cancer, endocrine diseases, inflammatory bowel diseases and
anti-inflammatory (other than aspirin) medications, oral
anticoagulant treatments (other than heparin), and hormone,
cytokine, or growth factor therapies.
2.2. Study Endpoints and Power Calculation. The primary
endpoint of the study was to determine whether intraplaque
levels of CRP at the time of CEA could predict the occurrence
of MACEs, defined as fatal or nonfatal acute coronary
syndrome and stroke, over an 18-month follow-up period.
The secondary endpoint consisted in determining potential
correlations between CRP and inflammation parameters,
both in serum and within carotid plaques. Two independent
investigators who were blinded to the biochemical and histo-
logical analyses adjudicated the study endpoints. Information
was obtained during a check-up visit at 18 months following
CEA and further confirmed by checking patients’ medical
files. All the endpoints were calculated based on data available
for carotid plaques of 217 patients.
The sample size was computed based on a previous study
showing a local difference of CRP levels in patients with
stable and vulnerable carotid atherosclerotic plaques [15].
According to our power calculation for logrank test, the
minimal sample size requested to detect a fourfold increase
in the risk of a MACE [21] with a power of 80% and a two-
sided alpha error of 5% was of 138 patients.
2.3. Detection of Biochemical and Inflammatory Biomarkers.
Routine autoanalyzers were used to assay hematological
parameters and blood chemistry, including total choles-
terol, low- and high-density lipoprotein cholesterol, triglyc-
erides, fibrinogen, and glycaemia. Serum levels CRP and
interleukin- (IL-) 6 were measured by colorimetric enzyme-
linked immunosorbent assay (ELISA) following the man-
ufacturer’s instructions (R&D Systems, Minneapolis, MN).
The limits of detection were 31.25 pg/mL for CRP and
0.156 pg/mL for IL-6. Mean intra- and interassay coefficients
of variation were <8% for all markers measured by ELISA.
2.4. Carotid Plaque Processing. Within few minutes after
surgical excision, the internal carotid plaque specimens were
transferred at 4∘C to the laboratory for processing [20, 22].
All atherosclerotic plaques were cut perpendicular to the long
axis through the point of maximum stenosis to obtain both
an upstream and a downstream portion. Each portion was
further divided perpendicular to the long axis in the middle
in two subsegments. Half was snap-frozen in liquid nitrogen
and stored at −80∘C (mRNA isolation), and the other half
was frozen in cryoembeddingmedium (OCT) for histological
analyses.
2.5. Oil Red O and Sirius Red Staining on Carotid Plaques.
Each portion frozen for histology was then divided into
8 sections, cut at an interval of 105 𝜇m from each other,
and stained with oil red O or sirius red, as previously
described [20, 22]. The sections were photographed under
light microscopy in order to evaluate total collagen con-
tent and under polarization microscopy. Interstitial collagen
subtypes were evaluated using polarized light illumination;
under this condition thicker type I collagen fibers appeared
orange or red, whereas thinner type III collagen fibers were
yellow or green. Total, type I, and type III collagen content
were quantified by MetaMorph 6 software. Results were
presented as percentages of stained area on total lesion area.
2.6. Immmunostaining of Endarterectomy Specimens. For
each portion, the eight sections cut at 105 𝜇m intervals
from each other were fixed in acetone at room temperature
and immunostained with specific antibodies. Primary anti-
bodies, such as anti-human smooth muscle actin (smooth
muscle cells (SMC); dilution: 1 : 100; Dako Corporation,
Glostrup, Denmark), anti-human CD66b (neutrophils; dilu-
tion: 1 : 50; Beckman Coulter, Nyon, Switzerland), and anti-
human CRP (dilution: 1/100; Sigma-Aldrich, Saint Louis,
MI), were used. For detecting macrophages, we used anti-
human CD68 (marker of total macrophages; dilution: 1 : 100;
Dako Corporation, CA), anti-human CD86 (marker of M1
macrophages; dilution: 1 : 100; GeneTex Inc., Irvine, CA),
anti-human HLA-DR (marker of M1 macrophages; dilution:
1 : 100; Dako Corporation), and anti-human CD163 (marker
of M2 macrophages; dilution: 1 : 50; AbD Serotec, Oxford,
UK) [26]. Quantifications were performed usingMetaMorph
6 software. Data were presented as percentages of stained area
on total lesion area.
2.7. Real-Time Reverse Transcription-Polymerase Chain Reac-
tion (RT-PCR). Total mRNA was isolated with Tri-Reagent
(MRC Inc.) from the upstream and downstream portions
of carotid artery plaques. Reverse transcription was per-
formed using the ImProm-II Reverse Transcription System
(Promega, Madison, WI, USA) according to the manufac-
turer’s instructions. RT-PCR (StepOne Plus, Applied Biosys-
tems, Foster City, CA, USA) was carried out with the ABso-
luteTM QPCR Mix (ABgene, Epsom, UK). Specific primers
and probes were used to determine the mRNA expression of
CRP and RPS13 (housekeeping gene) [27]: CRP forward, 5󸀠-
GCTTTTGGCCAGACAGACA-3󸀠; CRP reverse, 5󸀠-CGG-
TGCTTTGAGGGATACA-3󸀠; CRP Taqman probe, 5󸀠-CGA-
GGAAGGCTTTTGTGTTTCCC-3󸀠; RPS13 forward, 5󸀠-
CGTCCCCACTTGGTTGAAG-3󸀠; RPS13 reverse, 5󸀠-CCG-
ATCTGTGAAGGAGTAAGG-3󸀠; and RPS13 Taqman probe,
5󸀠-FAM-ACATCTGACGACGTGAAGGAGCAGATT-B-
HQ1-3󸀠. The fold change of mRNA levels was calculated by
the comparativeCtmethod.ThemeasuredCt valueswere first
normalised to the RPS13 internal control, by calculating delta
Ct (ΔCt).This was reached by subtracting the RPS13 Ct values
from the gene of interest Ct value. A delta delta Ct (ΔΔCt)
was calculated by subtracting the designated baseline control
group ΔCt value from the study group ΔCt values. The ΔΔCt
was then projected as a relative fold change with the following
formula: 2-ΔΔCt.
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2.8. Statistical Analysis. Analyses were performed with IBM
SPSS Statistics forWindows, version 23.0 (IBMCo., Armonk,
NY), and MedCalc 12.5 (MedCalc Software, Ostend, Bel-
gium). In the clinical study, categorical data are presented as
relative and absolute frequencies, whereas continuous vari-
ables are expressed as median and interquartile range (IQR).
Intergroup comparisons were drawn by Fisher’s exact test
andMann–Whitney𝑈 test, as appropriate. Ranked Spearman
correlation coefficients were performed to establish corre-
lations between serum and intraplaque biomarkers in both
upstream and downstream portions of carotid plaques. The
prognostic ability of CRP was evaluated on the basis of a
receiver operator characteristic (ROC) curve, usingMedCalc
12.5 (MedCalc Software, Ostend, Belgium). The area under
the curve (AUC) was given with 95% confidence interval (CI)
and the cut-off point of CRP was calculated maximizing the
sensitivity in accordance with Youden’s index. Kaplan-Meier
survival analysis with logrank test was performed to estimate
the cumulative event rate during 18 months after CEA and
to calculate the corresponding risk difference according to
CRP. Finally, the effect of CRP expression on MACE risk was
estimated byCox proportional hazardsmodels and expressed
with hazard ratios (HR) and 95% CI. In the multivariate
model, we adjusted for age, male gender, serum hs-CRP level,
and statin use. For all statistical analyses a two-sided 𝑝 value
<0.05 was considered as statistically significant.
3. Results
3.1. Patient Characteristics. Clinical and laboratory charac-
teristics of the cohort are listed in Tables 1 and 2, respectively.
Patient median age was 72 years, with a higher prevalence
of males (62.7%) and hypertensive and dyslipidemic patients
(72.4% and 57.6%, resp.) (Table 1). The median value of total
white blood cells (WBC) was 7.10 × 109/L, while the median
value of serum hs-CRP was 2.38mg/mL, suggesting low-
grade systemic inflammation (Table 2).
3.2. Intraplaque but Not Systemic CRP Levels Correlate with
Parameters of Inflammation within Atherosclerotic Plaques.
Downstream portions of carotid plaques were characterized
by increased neutrophil and M1 macrophage (CD86+ cells)
content when compared to upstream regions (Table 3).
Upstreamportions of carotid plaques had significantly higher
collagen (total, type I, and type III), smooth muscle cells
(SMC), and M2 macrophage subsets when compared to
downstream portions (Table 3). CRP expression in carotid
samples at both the mRNA and protein level showed that
intraplaque CRP content was well detectable at protein level
in all samples of upstream and downstream portions of
carotid plaques (Figure 1). The weak increase in intraplaque
CRP levels noted in upstream as compared with downstream
portions was nonsignificant (𝑝 = 0.070) (Table 3; Figure 1).
Conversely, intraplaqueCRPmRNAwas almost undetectable
(upstream plaques: detectable (i.e., <40 cycles at RT-PCR) in
29 of total 217 patients; downstream plaques: detectable in 29
of total 217 patients; data not shown).
In upstream portions, intraplaque CRP was directly
correlated with neutrophils (𝑟 = 0.208; 𝑝 = 0.008), total
Table 2: Laboratory findings of the overall cohort at admission.
Overall cohort (𝑛 = 217)
Hematology
Total WBC∗, number × 109/L (IQR) 7.10 (6.18–8.30)
Neutrophils, number × 109/L (IQR) 4.54 (3.55–5.46)
Lymphocytes, number × 109/L (IQR) 1.77 (1.42–2.15)
Monocytes, number × 109/L (IQR) 0.44 (0.35–0.55)
Platelets, number × 109/L (IQR) 229 (189.50–276.50)
Red blood cells, number × 1012/L (IQR) 4.70 (4.40–4.95)
Chemistry
Serum total-c†, mg/dL (IQR) 194 (165–224.25)
Serum LDL-c‡, mg/dL (IQR) 114.90 (88.20–142.75)
Serum HDL-c§, mg/dL (IQR) 49 (41.25–61.75)
Serum TAG‖, mg/dL (IQR) 118 (90–162.25)
Fibrinogen, mg/dL (IQR) 3.69 (3.15–4.24)
Fasting glycemia, mg/dL (IQR) 101 (91–115.75)
hs-CRP#, 𝜇g/mL (IQR) 2.38 (0.90–4.95)
IL-6∗∗, pg/mL (IQR) 2.16 (0.68–3.83)
Data are expressed as median (interquartile range [IQR]) or number
(percentages [%]).





#hs-CRP: high sensitivity c-reactive protein.
∗∗IL: interleukin.
macrophages (𝑟 = 0.158; 𝑝 = 0.046), and M1 subset (HLA-
DR+ cells, 𝑟 = 0.161; 𝑝 = 0.042), whereas it was inversely
correlated with SMC (𝑟 = −0.315; 𝑝 < 0.001) (Table 4).
In downstream portions, intraplaque CRP directly correlated
with M1 (CD86+, 𝑟 = 0.193; 𝑝 = 0.014; HLA-DR+ cells,
𝑟 = 0.226; 𝑝 = 0.004) and M2 macrophage subsets (CD163+,
𝑟 = 0.344, 𝑝 < 0.001) (Table 4). No correlation was
found between serum hs-CRP and intraplaque parameters
of vulnerability, within both upstream and downstream
portions of carotid plaques (Table 5).
3.3. CRP Levels in the Downstream Portion of Carotid Plaques
Predict FutureMACEs. ROCcurve analysis showed that CRP
content in upstream (Figure 2(a)) but not in downstream
(Figure 2(b)) portions of carotid plaques had significant
prognostic accuracy to predict MACEs (AUC 0.700 [95% CI
0.623–0.770]; 𝑝 = 0.013). In accordance with the Youden
index, an upstream intraplaque CRP content of 2.9% was
identified as the best cut-off point, having a sensitivity of
62.5% and a specificity of 78.4% (Figure 2(a)). After dividing
upstream plaques into low (≤2.9%) and high (>2.9%) CRP
groups, Kaplan-Meier analysis indicated that patients with
high intraplaque CRP had a greater rate of MACEs than
patients with low CRP levels (Figure 3). Of the 8 MACEs
observed during the 18-month follow-up period, 5 occurred
in the groupwith highCRP levels and 3 in the lowCRP group.
Cox proportional hazard regression analysis confirmed the
abovementioned results. The risk of MACEs increased with
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Table 3: Distribution of inflammatory biomarkers within upstream and downstream portions of carotid plaques.
Upstream Downstream 𝑝 value
Neutrophil, cells/mm2 2.36 (0.93–5.93) 4.33 (1.20–10.68) 0.002
Total collagen, % 29.29 (18.28–38.57) 16.52 (8.39–22.11) <0.001
Collagen I, % 10.29 (5.37–15.20) 5.30 (2.39–8.23) <0.001
Collagen III, % 12.14 (8.20–18.23) 5.28 (2.93–8.98) <0.001
CRP∗, % 1.54 (0.61–2.78) 1.04 (0.44–2.18) 0.070
Smooth muscle cells, % 4.53 (3.01–9.00) 2.78 (1.53–4.27) <0.001
Total macrophages (CD68+)†, % 5.80 (2.72–10.23) 6.47 (2.24–13.94) 0.205
M‡1 subset (CD86+), % 1.33 (0.49–3.06) 3.21 (1.24–7.11) <0.001
M1 subset (HLA-DR+)§, % 10.47 (6.07–18.30) 9.50 (5.81–14.30) 0.124
M2 subset (CD163+), % 1.66 (0.56–3.83) 1.37 (0.22–3.30) 0.049
Data are expressed as median (interquartile range [IQR]).
∗CRP: c-reactive protein.
†CD: cluster of differentiation.
‡M: macrophage.







Figure 1: Representative microphotographs of human carotid atherosclerotic plaques. Immunostainings for total lipid content (oil red O)
and CRP in upstream and downstream portions of human carotid artery plaques were performed. The arrows show CRP-positive areas.
increased CRP intraplaque content in the upstream portions
of plaques (HR 6.22 [95% CI 1.49–26.05]; 𝑝 = 0.012)
(Table 6). These results remained statistically significant also
after adjustment for age, male gender, hs-CRP, and statin use
(HR 8.57 [95% CI 1.89–38.77]; 𝑝 = 0.005) (Table 6).
4. Discussion
This study shows that intraplaque but not systemic CRP levels
are associated with different inflammatory parameters of
plaque vulnerability, particularly with regard to the upstream
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Table 4: Correlation between intraplaque CRP and inflammatory biomarkers in upstream and downstream plaques.
Upstream Downstream
CRP∗, % vs. 𝑟 𝑝 value CRP∗, % vs. 𝑟 𝑝 value
Neutrophils/mm2 0.208 0.008 Neutrophils/mm2 0.087 0.275
Total collagen, % 0.063 0.430 Total collagen, % −0.035 0.659
Collagen I, % −0.008 0.918 Collagen I, % −0.046 0.560
Collagen III, % −0.138 0.082 Collagen III, % −0.030 0.710
Smooth muscle cells, % −0.315 <0.001 Smooth muscle cells, % 0.028 0.726
Total macrophages (CD68+)†, % 0.158 0.046 Total macrophages (CD68+)†, % 0.097 0.222
M‡1 subset (CD86+), % 0.113 0.151 M‡1 subset (CD86+), % 0.193 0.014
M1 subset (HLA-DR+)§, % 0.161 0.042 M1 subset (HLA-DR+)§, % 0.226 0.004
M2 subset (CD163+), % 0.031 0.694 M2 subset (CD163+), % 0.344 <0.001
Correlations were performed by Spearman’s rank correlation coefficient.
∗CRP: high sensitivity c-reactive protein.
†CD: cluster of differentiation.
‡M: macrophage.
§HLA-DR: human leukocyte antigen-antigen D related.
Table 5: Relationship between serum hs-CRP and intraplaque parameters.
Upstream Downstream
hs-CRP∗, 𝜇g/mL vs. 𝑟 𝑝 value hs-CRP∗, 𝜇g/mL vs. 𝑟 𝑝 value
Neutrophils/mm2 0.045 0.547 Neutrophils/mm2 0.107 0.147
Total collagen, % −0.108 0.150 Total collagen, % −0.017 0.819
Collagen I, % −0.118 0.116 Collagen I, % 0.103 0.167
Collagen III, % −0.038 0.614 Collagen III, % 0.064 0.393
CRP, % −0.088 0.268 CRP, % −0.013 0.871
Smooth muscle cells, % −0.053 0.482 Smooth muscle cells, % −0.031 0.673
Total macrophages (CD68+)†, % 0.016 0.832 Total macrophages (CD68+)†, % 0.056 0.451
M‡1 subset (CD86+), % 0.038 0.630 M‡1 subset (CD86+), % −0.101 0.207
M1 subset (HLA-DR+)§, % −0.098 0.222 M1 subset (HLA-DR+)§, % −0.034 0.671
M2 subset (CD163+), % 0.055 0.481 M2 subset (CD163+), % −0.055 0.485
Correlations were performed by Spearman’s rank correlation coefficient.
∗CRP: high sensitivity c-reactive protein.
†CD: cluster of differentiation.
‡M: macrophage.
§HLA-DR: human leukocyte antigen-antigen D related.
Table 6: Cox proportional hazardsmodel showing the predictive value of upstreamCRP expression (cutoff> 2.9%) towardMACEoccurrence
during 18 months of follow-up.
Univariate model Multivariate model
HR∗ 95% CI† 𝑝 value HR 95% CI 𝑝 value
MACEs‡
Upstream CRP§ 6.22 1.49–26.05 0.012 8.57 1.89–38.77 0.005
Age 0.96 0.90–1.03 0.286 0.93 0.84–1.02 0.142
Gender, male 1.01 0.30–3.46 0.984 0.63 0.144–2.81 0.550
hs-CRP‖ 0.78 0.57–1.06 0.114 0.49 0.23–1.01 0.053
Statin use 1.65 0.48–5.64 0.423 1.41 0.32–6.22 0.648
∗HR: hazards ratio.
†CI: confidence interval.
‡MACEs: major adverse cardiovascular events.
§CRP: c-reactive protein.
‖hs-CRP: high sensitivity c-reactive protein.









































Figure 2: Receiver operator characteristic (ROC) curve analysis for CRP expression in upstream and downstream portions of carotid plaques.
The predictive value of CRP expression toward the occurrence of major adverse cardiovascular events (MACEs) at 18-month follow-up was












p = 0.0042 (logrank test)
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Upstream CRP ≤2.9% (n = 123)
Figure 3: High upstream expression of CRP is associated with an
increased rate of major adverse cardiovascular events (MACEs) at
18-month follow-up. Kaplan-Meier curve according to high (CRP:
>2.9%) and low (CRP: ≤2.9%) CRP expression levels in upstream
regions.
portions of carotid plaques. These findings might apparently
be in contrast with previous studies demonstrating that
serum CRP levels were positively associated with plaque vul-
nerability parameters [28–30]. On the other hand, CRP was
already demonstrated to localize within early atherosclerotic
plaques in human coronary arteries [31]. The proatheroscle-
rotic role of “local” CRP deposits was presumed to actively
contribute to intraplaque inflammation by recruiting mono-
cyte/macrophages, promoting foam cell formation and
inducing complement activation [32–35]. Devaraj and Jialal
demonstrated a pivotal activity of CRP in polarizing human
monocyte differentiation toward a proinflammatory M1
macrophage phenotype (via NF𝜅b and by binding to the Fc-𝛾
receptors CD32 and CD64) and inhibiting M2 macrophages
[36]. The pathophysiological relevance of intraplaque CRP
was further supported by its positive association with clinical
instability of CAD patients [18, 37]. Considering the hetero-
geneity of atherosclerotic plaques, the main novelty of our
study was the demonstration that intraplaque CRP levels can
differentially be associated with plaque vulnerability parame-
ters, depending onwhere the plaque is positioned. In particu-
lar, CRP levels within plaque portions located upstreamof the
stenosis were positively correlatedwith vulnerability parame-
ters (i.e., neutrophils and proinflammatoryM1macrophages)
and negatively correlated with protective mediators (such as
SMC). Differently fromWilson and coworkers [38], we were
not able to show the positive association between intraplaque
CRP protein andmRNA levels. In fact, CRPwas detectable in
only a few samples in the absence of relevantmRNAdegrada-
tion.These results are in partial contrast with the assumption
that intraplaque cells (vascular or inflammatory) might be
able to express and release CRP [39]. Considering that a
modest intraplaque amount of CRP was detectable in almost
all carotid plaque samples, we might hypothesize that CRP
infiltrates the subintimal region via the bloodstream [40].
We already speculated in 2008 about vascular CRP (localized
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within atherosclerotic plaques) as a promising CV risk factor
that might play an active proatherosclerotic “intraplaque”
role. These properties of intraplaque CRP might represent an
interesting issue potentially explaining the reason why CRP
serum levels were not related with the cardiovascular risk in
several clinical articles [9]. To date, no clear evidence of the
molecular and cellular mechanisms underlying intraplaque
CRP infiltration versus production has been produced. The
marginal role of CRP in mouse models of atherosclerosis did
not help to improve knowledge. Taking into the account these
limitations, and also confirming previous results [41, 42], our
observational study only supports CRP intraplaque content
as a proinflammatory mediator in human atherogenesis,
without clarifying the mechanistic insights.
On the other hand, wewere unable to find any association
between serum concentrations of CRP and any intraplaque
parameter of vulnerability. hs-CRP levels have previously
been shown to be associated with atherothrombotic coronary
plaques [43]. In addition, results from clinical trials have
suggested serum hs-CRP as being a reliable parameter to
monitor the efficacy of statin therapy in patients suffer-
ing from ST-elevation myocardial infarction [44]. Finally,
some positive association between carotid plaque inflamma-
tion/vulnerability and circulating inflammatory biomarkers
(i.e., CRP, tumor necrosis factor-𝛼, and IL-6) has already
been described [45, 46]. In contrast with the latter studies,
our findings on systemic CRP were surprising in that they
corroborate the findings by Grufman and colleagues that
showed no significant association between plasma hs-CRP
and intraplaque cytokine levels [47].
Another relevant finding of our study is the CV predictive
value of CRP levels in upstream portions of carotid plaques.
CRP content greater than 2.9% was correlated with a sixfold
increase in the probability of MACEs, in both univariate
and multivariate analyses. Moreover, upstream CRP content
predicted MACEs independently of age, male gender, hs-
CRP, and statin use. At the best of our knowledge, this is the
first time that intraplaque but not circulating CRP levels were
strongly correlated with MACEs in a cohort of patients with
severe carotid stenosis.
This study has some limitations. First of all, the relative
small sample size (𝑛 = 217) and the involvement of a
single center limited the generalization of the results. We are
looking tomatch our data with other carotid plaque biobanks
but have so far failed to identify any with tissues available
for protein and mRNA analysis. In addition, as previously
acknowledged, we were not able to identify the precise
mechanism by which CRP is deposited within the plaque.
In conclusion, CRP was stained at a protein level within
carotid plaques despite almost undetectable mRNA levels.
Intraplaque CRP directly correlates with parameters of vul-
nerability (such as M1 macrophage subset). High CRP levels
(>2.9%) in the upstream portions of atherosclerotic plaques
can predict MACEs at 18-month follow-up. On the contrary,
serumhs-CRP levels were neither associatedwith intraplaque
parameters of vulnerability nor associated with MACEs. Our
results, even if preliminary, indicate that intraplaque rather
than systemic CRP might be a proatherosclerotic factor
potentially useful to better assess the CV risk in patients
suffering from severe carotid atherosclerosis. Further studies
are required to validate intraplaque CRP as a reliable marker
of subclinical atherosclerotic disease.
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[17] P. Calabró, J. T. Willerson, and E. T. H. Yeh, “Inflammatory
cytokines stimulated C-reactive protein production by human
coronary artery smooth muscle cells,” Circulation, vol. 108, no.
16, pp. 1930–1932, 2003.
[18] M. Meuwissen, A. C. van der Wal, H. W. M. Niessen et al.,
“Colocalisation of intraplaque C reactive protein, complement,
oxidised low density lipoprotein, and macrophages in stable
and unstable angina and acute myocardial infarction,” Journal
of Clinical Pathology, vol. 59, no. 2, pp. 196–201, 2006.
[19] F. Montecucco, N. Vuilleumier, S. Pagano et al., “Anti-
Apolipoprotein A-1 auto-antibodies are active mediators of
atherosclerotic plaque vulnerability,” European Heart Journal,
vol. 32, no. 4, pp. 412–421, 2011.
[20] F. Montecucco, V. Di Marzo, R. F. Da Silva et al., “The activa-
tion of the cannabinoid receptor type 2 reduces neutrophilic
protease-mediated vulnerability in atherosclerotic plaques,”
European Heart Journal, vol. 33, no. 7, pp. 846–856, 2012.
[21] N. Vuilleumier, F. Montecucco, G. Spinella et al., “Serum levels
of anti-apolipoprotein A-1 auto-antibodies and myeloperoxi-
dase as predictors of major adverse cardiovascular events after
carotid endarterectomy,”Thrombosis and Haemostasis, vol. 109,
no. 4, pp. 706–715, 2013.
[22] F.Montecucco, S. Lenglet, A. Gayet-Ageron et al., “Systemic and
intraplaquemediators of inflammation are increased in patients
symptomatic for ischemic stroke,” Stroke, vol. 41, no. 7, pp. 1394–
1404, 2010.
[23] H. J. M. Barnett, D. W. Taylor, M. Eliasziw et al., “Benefit of
carotid endarterectomy in patients with symptomatic moderate
or severe stenosis,” The New England Journal of Medicine, vol.
339, no. 20, pp. 1415–1425, 1998.
[24] C. Warlow, B. Farrell, A. Fraser, P. Sandercock, and J. Slattery,
“Randomised trial of endarterectomy for recently symptomatic
carotid stenosis: final results of the MRC European Carotid
Surgery Trial (ECST),” The Lancet, vol. 351, no. 9113, pp. 1379–
1387, 1998.
[25] MRC Asymptomatic Carotid Surgery Trial (ACST) Collabora-
tive Group, “Prevention of disabling and fatal strokes by suc-
cessful carotid endarterectomy in patients without recent neu-
rological symptoms: randomised controlled trial,” The Lancet,
vol. 363, no. 9420, pp. 1491–1502, 2004.
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